Loading
Orthocell Limited Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest, by Unknown, was filed 20 Jul 2026.
Orthocell Limited: what insiders have been doing
This page follows insider dealings at Orthocell Limited as filed with ASX. From 18 October 2025 to 18 October 2026, the disclosure feed for Orthocell Limited logged 4 filings by 1 insider.
Every open-market trade in the period is a purchase: 4 purchases worth €45k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 senior executive. One trade stands out by size: a purchase of €14k, disclosed on 3 May 2026.
The clock since the last published purchase (20 July 2026) now reads 90 days.
With 4 filings in twelve months, the company is in line with the median of 4 filings across the 1,605 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 4 purchases and no sales.
This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
€45,097
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleUnknown4 buys
Since the insiders bought
- Unknown-6.9%Entry A$0.72 · Close 16 Oct 2026 A$0.67
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 17,280 of 23,476 companies
35.7
score / 100
Value19
Quality52
FCF yld-6.9%
Earn yld-6.9%
EV/EBITDA·
ROE-57%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
A$0.75
Analyst consensus
2 analystsA$1.13Target A$1.14(+53%)A$1.15
Income statement
RevenueA$11.4M
Gross profitA$11.4M100% margin
EBITDA-A$18.4M-161% margin
Net income-A$13.9M-122.0% margin
Valuation
PER (forward)-49.7x
P/Book5.9x
Beta-0.06
Balance sheet & cash
Market capA$202.9M
Total debtA$970.2k
Free Cash Flow-A$14M
Debt / Equity3%
Profitability & ownership
ROE-56.8%
ROA-25.5%
% insiders16.6%
% institutions2.3%
Last declaration on 20 July 2026
About Orthocell Limited
Orthocell Limited is an Australian Securities Exchange listed company focused on developing tissue regeneration solutions. It specializes in innovative treatments for musculoskeletal injuries and conditions.
